Age, genetic predisposition, and the presence of comorbidities, including diabetes, hypertension, and obesity, may further modulate the severity of fatigue and cerebrovascular complications post-COVID-19 through the interaction with DPPIV activity [101]. This evidence concerns the gene DPP4 and Hypertension.